Daniel Koller: Three decades of biotech evolution

US still offering the most biotech names

Over the past three decades, the biotech industry has witnessed remarkable growth and advances in drug development.

While 30-years ago biotechnology was a very young industry with a few dominant players such as Genentech, Amgen and Biogen, there is now a broad mix of large companies, start-ups and smaller providers with research and development candidates. European Assets appoints International Biotech trust chair to its board Then, as now, the US had the largest number of investable listed and private biotech companies and remains by far the most developed market for biotech investments today. Listed biotech companies in US and Europe today achieve revenues of over $200bn, which corresponds to ...